AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
AAPL   263.17 (-3.78%)
FB   187.24 (-1.32%)
MSFT   157.13 (-0.66%)
GOOGL   1,277.70 (-2.83%)
AMZN   1,841.11 (-2.29%)
NVDA   253.94 (+0.53%)
TSLA   632.73 (-6.81%)
AMD   42.80 (-2.75%)
T   34.42 (-3.67%)
F   6.75 (-3.16%)
BAC   27.93 (-4.12%)
DIS   114.54 (-2.97%)
Log in

NASDAQ:RXII - RXi Pharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range
$0.36
MA: $0.42
$0.50
52-Week Range N/A
Volume190,336 shs
Average Volume1.73 million shs
Market Capitalization$41.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RXII
CUSIPN/A
Phone508-767-3861

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$0.77 per share

Profitability

Net Income$-12,450,000.00
Net Margins-4,990.20%

Miscellaneous

EmployeesN/A
Market Cap$41.39 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RXII News and Ratings via Email

Sign-up to receive the latest news and ratings for RXII and its competitors with MarketBeat's FREE daily newsletter.


RXi Pharmaceuticals (NASDAQ:RXII) Frequently Asked Questions

What is RXi Pharmaceuticals' stock symbol?

RXi Pharmaceuticals trades on the NASDAQ under the ticker symbol "RXII."

When did RXi Pharmaceuticals' stock split? How did RXi Pharmaceuticals' stock split work?

RXi Pharmaceuticals's stock reverse split on the morning of Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of RXi Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Corp (NASDAQ:RXII) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analysts' expectations of $0.02 million. RXi Pharmaceuticals had a negative return on equity of 412.15% and a negative net margin of 4,990.20%. View RXi Pharmaceuticals' Earnings History.

Has RXi Pharmaceuticals been receiving favorable news coverage?

Media headlines about RXII stock have trended extremely negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. RXi Pharmaceuticals earned a daily sentiment score of -4.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for RXi Pharmaceuticals.

Who are some of RXi Pharmaceuticals' key competitors?

What other stocks do shareholders of RXi Pharmaceuticals own?

Who are RXi Pharmaceuticals' key executives?

RXi Pharmaceuticals' management team includes the folowing people:
  • Dr. Geert Cauwenbergh, Pres, CEO, Acting CFO & Director (Age 64)
  • Dr. Gerrit Dispersyn Dr. Med. Sc, Chief Devel. Officer (Age 43)
  • Ms. Caitlin Kontulis, Sr. Director of Fin. & Sec. (Age 32)
  • Dr. Karen Bulock, Former VP of Research

How big of a company is RXi Pharmaceuticals?

RXi Pharmaceuticals has a market capitalization of $0.00 and generates $10,000.00 in revenue each year. The biotechnology company earns $-12,450,000.00 in net income (profit) each year or ($4.20) on an earnings per share basis. View Additional Information About RXi Pharmaceuticals.

What is RXi Pharmaceuticals' official website?

The official website for RXi Pharmaceuticals is http://www.rxipharma.com/.

How can I contact RXi Pharmaceuticals?

RXi Pharmaceuticals' mailing address is 257 SIMARANO DRIVE SUITE 101, MARLBOROUGH MA, 01752. The biotechnology company can be reached via phone at 508-767-3861 or via email at [email protected]


MarketBeat Community Rating for RXi Pharmaceuticals (NASDAQ RXII)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  369
MarketBeat's community ratings are surveys of what our community members think about RXi Pharmaceuticals and other stocks. Vote "Outperform" if you believe RXII will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RXII will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: What is the Coverage Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel